{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"I-PRISM","nct_id":"NCT02916771","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=i-prism-nct02916771. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"* Cycles 1-9\n\n  * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle\n  * Lenalidomide is administered orally on days 1-21 on a 28 days cycle\n  * Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle\n* Cycle 10-24\n\n  * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle\n  * Lenalidomide is administered orally on days 1-21 on a 28 days cycle\n* Supportive measures consistent with optimal patient care may be given throughout the study","label":"Ixazomib","type":"EXPERIMENTAL"}],"collaborators":["Celgene","Takeda"],"completion_date":{"date":"2025-01-08","type":"ACTUAL"},"conditions":["Smoldering Multiple Myeloma"],"enrollment":{"count":61,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Ixazomib","otherNames":["Ninlaro"],"type":"DRUG"},{"name":"Lenalidomide","otherNames":["Revlimid"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":["Decadron"],"type":"DRUG"}],"last_update":"2025-08-11","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"Phase II Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-01-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy","timeFrame":"2 years"}],"references":[{"citation":"Nadeem O, Aranha MP, Redd R, Timonian M, Magidson S, Lightbody ED, Alberge JB, Bertamini L, Dutta AK, El-Khoury H, Bustoros M, Laubach JP, Bianchi G, O'Donnell E, Wu T, Tsuji J, Anderson KC, Getz G, Trippa L, Richardson PG, Sklavenitis-Pistofidis R, Ghobrial IM. Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial. Nat Commun. 2025 Jan 3;16(1):358. doi: 10.1038/s41467-024-55308-5.","pmid":"39753553","type":"DERIVED"},{"citation":"Nadeem O, Aranha MP, Redd R, Timonian M, Magidson S, Lightbody ED, Alberge JB, Bertamini L, Dutta AK, El-Khoury H, Bustoros M, Laubach JP, Bianchi G, O'Donnell E, Wu T, Tsuji J, Anderson K, Getz G, Trippa L, Richardson PG, Sklavenitis-Pistofidis R, Ghobrial IM. Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone. medRxiv [Preprint]. 2024 Apr 19:2024.04.19.24306082. doi: 10.1101/2024.04.19.24306082.","pmid":"38699307","type":"DERIVED"}],"start_date":{"date":"2016-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT02916771"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/i-prism-nct02916771"}